Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Moderna, Inc.NASDAQ: MRNA

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses declines year over year

Q3 FY2026 other income / expenses of $41M fell 43.8% year over year, behind the -35.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 14.6% from the prior quarter. Over 3 fiscal years it compounded at +25.4% a year.

Context

  • Other income / expenses amounted to 15.7% of revenue in FY2025, up 5.2 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -43.8% toward the trailing-twelve-month pace of -35.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$41M-14.6% QoQ
Last fiscal yearDec 2025
$306M-9.5% YoY
LTMSep 2026
$201M-35.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.8%——
1 year-9.5%——
3-year CAGR+25.4%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
306M USD
Year-over-year change
-9.5%

Other Income / Expenses vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.2% is the 2nd highest of 10, against a peer median of -93.0%.
  • Other income / expenses amounts to 8.0% of revenue for MRNA, versus a peer median of 20.1%.
MRNA Competitors
Other Income / Expenses for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€260.88M EUR-46.5%—9.9%
MRNAModerna, Inc.LTM Sep 2026$201M USD-35.2%+25.4%8.0%
PCVXVaxcyte, Inc.LTM Jun 2026$101.03M USD-37.5%+161.6%—
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M USD-22.0%—23.2%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$1.21M USD-112.8%——
NVAXNovavax, Inc.LTM Mar 2026-$19.43M USD-125.2%—3.3%
VALNValneva SELTM Mar 2026-€38.24M EUR-120.8%—24.5%
GSKGSK plcLTM Jun 2026-£969M GBP-93.0%—2.9%
PFEPfizer Inc.LTM Jun 2026-$12.81B USD-109.5%—20.1%
Peer median (excluding MRNA) —-93.0%+161.6%20.1%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.